INTRODUCTION
Hematopoietic progenitor cells (HPCs) collected by apheresis of G-CSF-stimulated donors have surpassed bone marrow as the graft source of choice for hematopoietic stem cell transplantation in adults 1 . Peripheral blood HPC grafts are currently used successfully to treat hematologic and non-hematologic disorders, both benign and malignant [2] [3] [4] . Compared to bone marrow aspiration, their relative ease of collection by apheresis and the abundance of CD34+ cell yields make them the preferred source. However, significant variability in HPC yields has been reported even among healthy allogeneic donors. Demographic characteristics such as female sex, advancing donor age, lower body mass index (BMI), lower baseline platelet counts and lower G-CSF dose are known to be negatively correlated with CD34+ cell mobilization 5, 6 .
Racial differences in G-CSF-mediated HPC mobilization are less well characterized.
Physiologically, lower absolute neutrophil counts (ANC) are observed in African Americans (AAs) compared to Caucasians. Benign ethnic neutropenia (BEN) is described in about 5% of healthy AAs and is characterized by a decrease in granulocytes and monocytes with minimal differences in other white blood cell (WBC) subsets 7, 8 Postulated mechanisms for this phenomenon include a decreased stem cell reserve or fewer G-CSF receptors per cell among AA subjects. An association with the Duffy blood group antigen null phenotype, seen in 67% of AAs, and a consequent decrease in chemokine-mediated leukocyte recruitment has also been proposed [9] [10] [11] . Unstimulated cord blood units collected from AA donors are reported to have lower total nucleated counts (TNC) and CD34+ cell counts 12 . Further, studies show relatively decreased leukocyte demargination and corticosteroid-mediated leukocyte egress in healthy AA adults 13, 14 . Paradoxically, two recent clinical studies noted equivalent or increased G-CSFstimulated HPC yields among AAs compared to other races 5, 15 .
Healthy AAs also have lower hemoglobin and MCV compared to their Caucasian counterparts 16 .
Low MCV and iron deficiency among healthy donors, which may not affect stem cell mobilization, have been implicated in poor collection efficiencies (due to device-related abnormalities in cell separation mechanics), thus affecting final yields 17 .
The effect of sickle cell trait (SCT) among AA HPC donors was evaluated in a small study which showed a trend towards better peripheral blood mobilization but poorer apheresis collection efficiencies in sickle trait versus non-sickle trait AA subjects. This resulted in similar CD34+ cell apheresis yields among the two groups. Additionally, no significant adverse events were reported among AAs with or without SCT during the process of G-CSF-stimulation and HPC collection 18 . Despite these data, healthy AA donors who screen positive for SCT are currently excluded from unrelated donor registries.
Our primary objective was to compare G-CSF-stimulated CD34+ cell mobilization and HPC apheresis yields among healthy AA compared with Caucasian donors. Further, we evaluated the role of physiologic interracial differences, including that of sickle cell trait, in HPC mobilization and apheresis collection outcomes.
MATERIALS AND METHODS

Study subjects
We retrospectively analyzed 1,096 consecutive healthy allogeneic related and unrelated firsttime HPC apheresis donors who self-characterized their race as African American or
Caucasian. Given the possibility of biased results due to significant heterogeneity within the following groups, healthy donors who described their race as Hispanic, Asian, Pacific Islander, mixed and/or other were excluded. All donors were 14 years of age or older and were either healthy siblings enrolled in institutional transplant protocols or unrelated healthy volunteers 
HPC mobilization and collection
Subcutaneous injections of G-CSF were administered for 5 consecutive days at a daily dose of 10-16 mcg/kg, with the fifth dose given at least two hours prior to the start of the HPC apheresis procedure. The actual dose administered was obtained from a review of pharmacy and nursing records. Apheresis procedures were performed on the CS-3000 Plus continuous-flow apheresis device (Fenwal Division, Baxter, Deerfield, IL) or a COBE Spectra Apheresis device (Terumo BCT, Lakewood, CO) using prophylactic intravenous calcium infusions as previously described 19 . CD34+ collection efficiencies were similar using the two devices in our center.
Volume processed per procedure ranged from 6 to 33 liters (L) for HPC collections (mean + SD, 19 + 5 L), depending on the immediate pre-apheresis CD34+ cell count and the targeted cell dose, and from 3 to 25 L (11 + 3 L) for lymphapheresis procedures. Details of the study design are shown in Figure 1 .
Laboratory data
Complete blood count (CBC) including a differential and RBC indices were obtained at baseline,
i.e. prior to G-CSF administration or, in patients who underwent lymphapheresis collections, prior to lymphapheresis, and were repeated on the day of collection, immediately prior to and following apheresis. Serology records for ABO, Rh and Duffy red cell phenotype were gathered from the Department of Transfusion Medicine database. Donor hemoglobin electrophoresis data were collected from all AA and selected Caucasian subjects at baseline to determine the presence of sickle cell and/or thalassemia traits. CD34+ cell quantitation was performed on peripheral blood immediately pre-apheresis (2 hours after the 5th dose of G-CSF), postapheresis, and on the apheresis product by flow cytometry as previously described. 20 Flow cytometric techniques did not change significantly during the 14 year period covered in this review.
Statistical analysis
The total mononuclear cell count was calculated as the sum of lymphocyte and monocyte counts reported on the CBC differential. Collection efficiencies were calculated using the
CD34+ cell content in product x 100
(Mean of pre-and post-apheresis CD34+ counts) x (Volume processed) Summary statistics were calculated for all numerical data. Two-tailed unpaired Student t-tests were used to compare groups of two with a presumed normal distribution. Analysis of variance was used to compare more than 2 groups. Categorical variables were compared using a 2-tailed Fisher exact test. Multivariate analyses were performed using stepwise forward logistic regression, based on parameters having significance in univariate analysis, using a commercial statistics program (JMP, Version 7, SAS Institute Inc., Cary, NC). Results are given as the mean + SD. A p value of <0.01 was considered significant.
RESULTS
Donor demographics
All AA (n=215) and Caucasian (n=881) donors with complete data sets were included. Sex ratio was similar among the two groups (45 vs 52% male; p=0.09). AAs were younger (39 vs 43 years, p=0.001) and had greater weight (86 vs 81 kg, p=0.001) and BMI (30 vs 27; p<0.0001)
than Caucasians. The total daily dose of G-CSF was greater in AAs than Caucasians (920 vs 850 mcg, p<0.0001) but the G-CSF dose/kg was similar in the 2 groups (Table 1) .
Donor race, CD34+ mobilization, and HPC apheresis cell yields
African Americans mobilized significantly better than Caucasians with mean peak circulating CD34+ counts of 123 vs 75 cells/uL (p<0.0001) ( Figure 2 ). CD34+ apheresis yield was also significantly greater in AAs than Caucasians (51 ± 35 vs 32 ± 21 x 10 6 cells per liter processed, p <0.0001), consistent with higher pre-apheresis counts. Apheresis collection efficiency was similar in the two racial groups (AAs, 64%; Caucasians, 62%; p=0.11). Lymphapheresis within the 7 days prior to starting G-CSF was associated with significantly improved CD34+ cell mobilization; however, the effect did not differ by race (Figure 3) .
In a univariate analysis of factors associated with higher peripheral blood CD34+ counts, three factors were overwhelmingly correlated with better peak CD34 mobilization: higher total G-CSF dose, African American race, and greater BMI, followed by higher baseline platelet and MNC counts, prior lymphapheresis, and male sex. After adjustment for total GCSF dose, AA race was the single parameter most strongly correlated with peak PB-CD34+ mobilization. In multivariate stepwise analysis, after total G-CSF dose and race were included in the model, donor BMI lost much of its contribution. Baseline platelet and MNC counts remained highly correlated, and after they were introduced into the model, prior lymphapheresis, male sex, and younger age remained significantly correlated with peak PB-CD34 counts (Table 2 ). To ensure that confounding factors were not introducing bias, the analysis was repeated by forcing all other parameters into the multivariate regression model and retaining race until the end; AA race still remained a significant predictor of better CD34 mobilization.
African Americans were significantly less likely than Caucasians to be poor mobilizers and significantly more likely to be super-mobilizers. A pre-apheresis CD34+ cell count of < 20/uL was seen in 1.4% vs 6.1%, and a CD34+ cell count of > 120/uL in 39.1% vs 13.5% of African
American versus Caucasian donors, respectively (p <0.001 for both comparisons) ( Table 3) .
Effect of G-CSF on laboratory parameters
Hemoglobin and mean corpuscular volume were significantly lower among AAs than
Caucasians, both at baseline and after G-CSF administration. Platelet counts were similar between the two groups, and showed a similar degree of decline following G-CSF 
G-CSF dose and CD34+ mobilization in African Americans and Caucasians
When stratified by G-CSF dose, at higher doses (16 mcg/kg/d), the difference in mobilization responses between the two groups was less apparent (peak CD34+ counts 123 vs 93 cells/uL, AA (n=33) vs Caucasian (n=73), p=0.07) than at lower doses (10 mcg/kg/d), where peak CD34 counts were 123 vs 74 cells/uL, AA (n=182) vs Caucasian (n=808), p<0.0001 ( 
Effect of sickle cell trait on CD34+ cell mobilization and HPC apheresis yields
African Americans with sickle cell trait (SCT) received significantly higher total G-CSF dose as well as G-CSF dose/kg, by protocol design, related to transplant preparative regimens in those who had siblings with sickle cell disease 3 . Despite this increased dose, in AA donors with known HbS status, the presence of SCT had no effect on CD34+ mobilization (peak CD34+ counts 123 ± 91 vs 107 ± 72 cells/uL, HbAS (n=41) vs HbAA (n=84), p=0.34). Although MCV was lower among AAs with SCT, collection efficiency was similar among AAs with and without SCT ( Table 6 ).
Adverse events
No significant difference in the incidence of severe adverse events (AE > grade 3 by CTCAE Lymphapheresis within the 7 days preceding G-CSF administration was found to enhance CD34+ mobilization and increase HPC apheresis yield. Platelet depletion during the prior lymphapheresis procedure may have resulted in a TPO-mediated increase in progenitor cells common to both megakaryocytes and HPCs. The increase was non-significant if lymphapheresis was performed greater than 7 days prior to GCSF administration, suggesting a transient HPC stimulant effect. Interestingly, a marginal decrease in platelet counts was observed following G-CSF administration, suggesting a competitive "steal" of common progenitors towards HPC production. The effects of lymphapheresis and the lowering of platelet counts with G-CSF were independent of race.
CD34+ cell collection efficiency was correlated in prior studies with iron deficiency and low MCV and was related to abnormal cell separation mechanics during apheresis 17 . In our cohort, African Americans demonstrated significantly lower MCV and hemoglobin levels than Caucasians both at baseline and following G-CSF administration; however, mean CD34+ collection efficiency was similar in both groups. It is likely that the value of the MCV is less important than the cause of a low MCV in terms of impact on apheresis device performance.
Iron deficiency is associated with the presence of red cells of highly variable size, as reflected in an elevated red cell distribution width (RDW). We have found that a high RDW in the presence of a low MCV is more likely to be associated with impaired leukapheresis collection efficiency than a low MCV alone. Sickle trait subjects had a normal RDW, thus explaining the lack of impact of the low MCV on CD34+ collection efficiency.
Common adverse events due to G-CSF injections include headaches, bone pain, myalgias, and insomnia. Occasionally, more severe adverse events such as splenic rupture, myocardial infarction and arrhythmias have been reported in healthy donors. Adverse events in our donor cohort were generally of mild to moderate severity and were similar to those reported in prior studies 25, 26 . In contrast, adverse effects of G-CSF can be significant in patients with sickle cell anemia and include cases of life-threatening sickling crisis 27 . One small randomized trial found that G-CSF mobilization and HPC apheresis were as safe in donors with sickle cell trait as they were in AA non-trait donors 18 . Yet donors with sickle cell trait are excluded from participation in the NMDP registry, based largely on a single case of G-CSF-associated multiorgan failure in a patient with compound heterozygous sickle cell/β+ thalassemia. 28 Since SCT is present in up to 10% of African Americans, eliminating these individuals also negatively impacts the unrelated donor pool. Our data include the largest number of consecutive AA donors with SCT yet reported to undergo G-CSF-assisted HPC collection, and demonstrate no differences in occurrence of severe adverse clinical events, efficacy of CD34 mobilization, efficiency of CD34 collection, or product loss during cryopreservation and thaw, compared with HPC donations from non-trait AA donors.
In conclusion, racial differences in G-CSF-mediated CD34+ cell mobilization are a novel clinical finding and occur in a direction paradoxical to that predicted by known physiologic mechanisms.
Further evaluation of race-associated genetic polymorphisms in relation to G-CSF pharmacokinetics may help improve G-CSF dosing strategies. Clinically, identifying donors at risk for either poor or exceptionally good mobilization may help transplant teams plan ahead and allocate resources appropriately. Finally, the absence of significant adverse clinical events or deleterious changes in product quality among donors with sickle cell trait may serve as the basis to revisit the possibility of including these individuals in unrelated donor registries. 
